Illumina concluded fiscal year 2025 with a strong fourth quarter, achieving a 5% increase in revenue to $1.16 billion and a significant rise in GAAP diluted EPS to $2.16. The company's non-GAAP operating margin also improved to 23.7%, indicating disciplined execution and momentum, particularly in clinical markets.

Illumina delivered strong Q3 2025 results, with revenue of $1.08 billion, flat year-over-year, and diluted EPS of $0.98. Non-GAAP diluted EPS reached $1.34, surpassing expectations. The company returned to growth outside of China, driven by acceleration in the clinical market segment.

Illumina delivered a solid second quarter in fiscal year 2025, with revenue of $1.06 billion, a GAAP diluted EPS of $1.49, and a non-GAAP diluted EPS of $1.19. The company exceeded its guidance, driven by strong performance in X consumables and accelerating growth in its clinical segment, despite a challenging funding environment in research. Operational excellence contributed to margin expansion, leading to increased full-year expectations.

Illumina reported first quarter 2025 Core Illumina revenue of $1.04 billion, a 1% decrease year-over-year. GAAP diluted EPS was $0.82 and non-GAAP diluted EPS was $0.97. The company updated its full-year 2025 financial guidance, reflecting anticipated impacts from geopolitical developments and tariffs, particularly affecting the Greater China region.

Illumina reported consolidated revenue of $1.08 billion for Q1 2024, a 1% decrease compared to Q1 2023. However, the company's gross margin and non-GAAP operating margin improved year-over-year, driven by a favorable mix of sequencing consumables and operational excellence. Illumina is reiterating its fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20%.

Illumina's Q4 2023 revenue reached $1.12 billion, a 4% increase from Q4 2022, driven by NovaSeq X instrument and consumables sales. The company's GAAP diluted loss per share was $(1.11), while non-GAAP diluted earnings per share were $0.14. Illumina is focused on driving top-line growth, operational excellence, and resolving GRAIL.

Illumina's Q3 2023 revenue was $1.12 billion, flat compared to Q3 2022. GAAP diluted loss per share was $(4.77), including $821 million in GRAIL-related impairments. Non-GAAP diluted earnings per share was $0.33, slightly down from $0.34 in Q3 2022. The company shipped 97 NovaSeq X instruments and updated its full-year guidance, expecting a revenue decrease of 2% to 3% from 2022.

Illumina's Q2 2023 consolidated revenue reached $1.18 billion, a 1% increase year-over-year (3% on a constant currency basis) and an 8% increase sequentially from Q1 2023. The company shipped 109 NovaSeq X instruments. GAAP diluted loss per share was $(1.48), while non-GAAP diluted earnings per share was $0.32.

Illumina reported strong financial results for the third quarter of fiscal year 2021, with revenue of $1,108 million, a 40% increase compared to the prior year period. GAAP net income was $317 million, or $2.08 per diluted share, and non-GAAP net income was $221 million, or $1.45 per diluted share.

Illumina reported a strong second quarter with record revenue of $1,126 million, a 78% increase compared to the prior year period. The company's performance was driven by clinical applications, including oncology and genetic disease testing, as well as research. As a result, Illumina raised its fiscal year 2021 financial guidance.

Illumina reported a record revenue of $1,093 million for the first quarter of fiscal year 2021, a 27% increase compared to the prior year period. GAAP net income for the quarter was $147 million, or $1.00 per diluted share, while non-GAAP net income was $278 million, or $1.89 per diluted share.

Illumina reported a record fourth quarter revenue of $953 million, a slight increase compared to the prior year period. GAAP net income was $257 million, or $1.75 per diluted share, while non-GAAP net income was $179 million, or $1.22 per diluted share. The company saw record orders, including sequencing instruments, and anticipates continued recovery from the pandemic in 2021.

Illumina's third quarter 2020 results showed strong sequential growth with revenue of $794 million, a 26% increase compared to the second quarter of 2020, although a 12% decrease compared to the prior year period. GAAP net income was $179 million, or $1.21 per diluted share, while non-GAAP net income was $150 million, or $1.02 per diluted share.

Illumina's second quarter 2020 revenue was $633 million, a 25% decrease compared to the second quarter of 2019. GAAP net income attributable to Illumina stockholders for the quarter was $47 million, or $0.32 per diluted share, compared to $296 million, or $1.99 per diluted share, for the second quarter of 2019.

Illumina's first quarter 2020 revenue increased by 2% to $859 million compared to $846 million in the first quarter of 2019. GAAP net income attributable to Illumina stockholders was $173 million, or $1.17 per diluted share, compared to $233 million, or $1.57 per diluted share, for the first quarter of 2019. Non-GAAP net income attributable to Illumina stockholders was $243 million, or $1.64 per diluted share, compared to $237 million, or $1.60 per diluted share, for the first quarter of 2019.

Illumina's Q4 2019 results showed a 10% revenue increase to $953 million compared to Q4 2018. GAAP net income attributable to Illumina stockholders was $239 million, or $1.61 per diluted share, and non-GAAP net income was $252 million, or $1.70 per diluted share. The company's cash flow from operations reached $443 million, with free cash flow at $386 million.